Reinforcement value enhancement by nicotine of nonnicotine rewards is believed to partially motivate smoking behavior. Recently, we showed that the value-enhancing effects of nicotine are well characterized by reinforcer demand models and that the value-enhancing effects of the smoking-cessation aid bupropion (Zyban) are distinct from those of nicotine and differ between the sexes. The present study evaluated potential sex differences in the enhancement effects of nicotine and varenicline (Chantix) using a reinforcer demand methodology. The role of α4β2* and α7 nicotinic acetylcholine receptors (nAChRs) in the enhancing effects of nicotine and varenicline is also evaluated. Male and female rats (n = 12/sex) were trained to lever press maintained by sensory reinforcement by visual stimulus (VS) presentations. Changes in the VS value following nicotine and varenicline administration were assessed using an established reinforcer demand approach. Subsequently, the effects of antagonism of α4β2* and α7 nAChRs on varenicline and nicotine-induced enhancement active lever-pressing were assessed using a progressive ratio schedule. Nicotine and varenicline enhanced VS demand equivalently between the sexes as evaluated by reinforcer demand. However, α4β2* receptor antagonism attenuated value enhancement by nicotine and varenicline in females, but only of nicotine in males.
Introduction
Among the leading causes of preventable death and disease in the world, tobacco use is the deadliest, accounting for over 480 000 deaths annually in the USA alone (U.S. Department of Health and Human Services, 2014) . Nicotine is commonly accepted to be the primary constituent of tobacco smoke responsible for smoking addiction. However, the primary rewarding effects of nicotine alone are markedly weak relative to the prevalence and tenacity of nicotine dependence (U.S. Department of Health and Humans Services, 1988; Caggiula et al., 2009) . Rather, it appears that the behavioral and neuropharmacological mechanisms by which nicotine reinforces smoking are more multifarious than simply primary reinforcement by nicotine . A mounting body of research recommends that a complete representation of the mechanisms by which nicotine maintains smoking must comprise primary reinforcement by nicotine, secondary reinforcement by nicotine-associated environmental stimuli, Pavlovian conditioning of the interoceptive stimulus effects of nicotine with non-nicotine reinforcers, and nicotinemediated enhancement of the value of non-nicotine reinforcers (for a review, see Bevins and Palmatier, 2004) .
Research has shown that males and females differ in smoking behavior and nicotine dependence, suggesting that a complete characterization of nicotine reward must also incorporate biological sex (Perkins et al., 1994 (Perkins et al., , 2002 Lynch et al., 2002; Roth et al., 2004; U.S. Department of Health and Human Services, 2001; Perkins, 2009 ). Specifically, additional research efforts are needed to determine how males and females may differ in the degrees to which the primary reinforcing, secondary reinforcing, reinforcer-enhancing, and interoceptive stimulus effects of nicotine contribute toward motivating smoking and relapse (Bevins and Palmatier, 2004) . Over a decade of research indicates that nicotine enhances the value of non-nicotine rewards, particularly sensory reinforcers, and this enhancement effect partially drives smoking maintenance (for a review, see Caggiula et al., 2009) . In addition, studies indicate that females are more sensitive to the sensory and contextual elements of smoking and less prone to the primary reinforcing effects of nicotine than males (Perkins, 2009) . Given the prominence of the enhancing effects of nicotine on sensory reinforcers and the greater contribution of sensory stimuli in the smoking behavior of females, the present study examined whether sex differences are apparent in the reward-enhancing effects of nicotine and varenicline. Varenicline is a compound of interest because it is one of the most commonly prescribed smoking-cessation aids (Chantix), shares a similar mechanism of action with nicotine, and has been shown to produce enhancement of operant behavior analogous to nicotine (Rollema et al., 2007; Levin et al., 2012; Schassburger et al., 2015) .
Behavioral economics provides several tools for assessing the value of reinforcers across differing conditions of consumption. In the present study, we used a reinforcer demand model (Hursh and Silberberg, 2008; Hursh, 2014) to quantifiably compare changes in the reinforcement value wrought by nicotine and varenicline between the sexes. The basic framework of this model conceptualizes reinforcement value in terms of reinforcer consumption as a function of its price in units of response cost. Reinforcer consumption decreases as the unit price of the reinforcer increases, and the rate of this decrease defines what is termed as elasticity of demand. Demand that is inelastic is relatively insensitive to increases in reinforcer price, and represents consumption that is primarily constrained by satiation. Elastic demand is characterized by proportionally marked decreases in consumption relative to increases in price, and represents consumption that is largely constrained by the cost to obtain the reinforcer. Importantly, the rate of change in elasticity of demand provides a metric of conditionspecific reinforcement value by representing the sensitivity to escalating reinforcer price. Recently, we showed that reinforcer demand modeling provides a richly detailed characterization of changes in reinforcement value by nicotine and bupropion . In the present study, we extend our previous work to the reward-enhancing effects of nicotine and varenicline in male and female rats using a similar reinforcer demand modeling technique.
In the present study, we extend previous research by evaluating the reward-enhancing effects of nicotine alongside those of varenicline, a commonly prescribed and relatively effective smoking-cessation aid. The reinforcer demand model was used to quantitatively characterize and compare the reward-enhancing effects of nicotine and varenicline, and to evaluate how the enhancement effects of each drug interact with biological sex. Like nicotine, varenicline acts as an agonist at α4β2-containing nicotinic acetylcholine receptors (nAChRs), although only partially, and acts as a full agonist at α7 and α3β4* (where * indicates additional unspecified subunits) nAChRs (Grady et al., 2010; Ortiz et al., 2012) . Considerable evidence suggests that β2-containing nAChRs on dopaminergic neurons in the midbrain regions of the ventral tegmental area and nucleus accumbens mediate the primary reinforcing effects of nicotine (Picciotto et al., 1998; Brunzell and Picciotto, 2009; Placzek and Dani, 2009; Picciotto and Mineur, 2014) . Varenicline exerts mixed agonist and antagonist effects on α4β2-containing nAChRs, which may account for its apparent lack of primary reinforcing effects (Grady et al., 2010; Ortiz et al., 2012; Schassburger et al., 2015) .
The present study investigated the involvement of the α4β2-containing and α7 nAChRs in the reward-enhancing effects of nicotine and varenicline on progressive ratio-maintained responding in male and female rats using antagonism by dihydro-β-erythoidine (DHβE) or methyllycaconitine (MLA).
Methods

Subjects
Twenty-four experimentally naive Sprague-Dawley rats (n = 12/sex; Harlan, Indianapolis, Indiana, USA), 9 weeks upon arrival, were individually housed in clear polycarbonate tubs lined with TEK Fresh cellulose bedding (Envigo; Huntingdon, Cambridgeshire, UK) in a temperature-controlled and humidity-controlled colony. Rats were given 2 days to acclimate to the colony, followed by 3 additional days of handling before initiation of training. Water was available continuously and rats were given 12 g (female) or 15 g (males) of laboratory chow daily, unless otherwise specified. Previous work in our laboratory has found this feeding regimen to be sufficient to maintain normal growth rates while being lean enough to stimulate exploratory behavior in both sexes. Sessions were conducted during the light phase of a 12 : 12 h light/ dark cycle. Experimental protocols were approved by the Institutional Animal Care and Use Committee, University of Nebraska (Lincoln, Nebraska, USA).
Apparatus
We used 16 conditioning chambers (ENV-008CT; Med-Associates Inc., St. Albans, Vermont; measuring 30.5 × 24.1 × 21.0 cm, L × W × H), enclosed in lightattenuating and sound-attenuating cubicles fitted with an exhaust fan. Sidewalls were aluminum; the ceiling and front and back walls were clear polycarbonate. One sidewall featured a dipper receptacle, occupying a 5.2 × 5.2 × 3.8 cm (L × W × H) recessed space, into which a dipper arm provided 0.1 ml of sucrose solution when raised. Retractable response levers were featured on either side of the dipper receptacle~5 cm above the rod floor. White 28-V DC (100 mA) lamps were located 3 cm above each lever, hereafter termed lever lights. Two 28-V DC (100 mA) houselights were also located above the conditioning chamber, but within the sound-attenuating cubicle. An infrared emitter/detector unit, positioned 4 cm above the floor, bisected the chamber 14.5 cm from the sidewall featuring the dipper receptacle and functioned to monitor chamber activity. Data collection and presentation of experimental events were controlled by a personal computer with Med-Associates Interface and Software (Med-PC for Windows, IV; Med-Associates Inc., Fairfax, Vermont, USA).
Acquisition
Rats were trained to lever press over four autoshaping sessions using 26% (weight/volume) liquid sucrose (cf. Charntikov et al., 2013) . Autoshaping sessions began with random insertion of one of the two levers. After a lapse of 15 s or a lever press, the response lever was immediately retracted and the dipper arm was raised for 4 s. Following a variable length timeout (average = 60 s, range = 30-90 s), the opposite lever was inserted into the chamber, initiating a new trial as just described. The lever inserted on odd numbered trials was always determined randomly, and the opposite lever always followed on even numbered trials. Thus, over a 60-trial session, each lever was inserted 30 times, but never presented more than twice in succession. Each session was conducted in continuous house-light illumination and no other stimuli were presented.
Over the following 10 days, rats were trained to lever press maintained by visual stimuli (VS), consisting of 60-s termination of house-light illumination compounded with 5-s illumination of lever lights. Active and inactive lever assignments were pseudo-randomly determined and counterbalanced. Daily sessions involved 60 min VS reinforcement delivered on a fixed-ratio (FR) 1 schedule (one response per reinforcer) for responding on the active lever; responses on the inactive lever were recorded, but had no programmed consequences. To familiarize the rats to injection procedures and to provide sufficient nicotine pre-exposure to minimize the response suppressant effects of nicotine, each rat received an injection of saline 5 min preceding placement into the chamber and an injection of nicotine 15 min following termination of each session. Previous work in our laboratory has found that rats tolerate the suppressant effects of nicotine within roughly 3 consecutive days.
Reinforcer demand assessment
Following the 10th day of FR 1 training, rats continued to lever press maintained by VS reinforcement in 60-min sessions, as described earlier. The response requirement was now increased systematically after the completion of each block of 16 sessions. The sequence of response costs followed an exponential base 2 sequence ranging from FR 1 to FR 256. Over different sessions within each FR block, rats received injections of 0.9% saline, nicotine (0.4 mg/kg), or varenicline (0.1 or 1.0 mg/kg) before placement in the apparatus. Sessions proceeded with the restriction that each drug condition was experienced once before repeating and no drug condition was experienced 2 days in succession. Drug and dose administration order was randomized and then counterbalanced across subjects, such that an equal number of subjects experienced each drug or dose condition on any given day. Each drug was tested four times within each FR block. However, only the last three were included in analyses to capture stable performance on each FR schedule (i.e. the terminal 12 sessions of each 16 session FR block). Demand assessment continued for each rat until the last session of FR 256 or until the last session of an FR block in which the mean number of VS presentations earned was less than one across all drug conditions. The demand model relates reinforcer consumption to unit response cost by Eq. (1) as follows:
in which Q reflects the units of reinforcer consumption, Q 0 is the predicted consumption in the absence of the constraint of cost (i.e. the ordinate intercept), k is a constant reflecting the range of the demand function in log units of consumption, e is the base of the natural logarithm, C is the response cost to obtain reinforcement, and α represents the rate of change in decline of consumption in standardized price (Q 0 × C). The values of Q 0 and α are permitted to vary to maximize the fit of the demand model and may be conceptualized to represent the basal intensity of demand (Q 0 ) and sensitivity to price (α) (Hursh and Silberberg, 2008; Hursh, 2014) . That is, Q 0 represents consumption where the only constraint is satiation and α reflects the limiting effects of both satiation and price on consumption by representing the rate at which consumption shifts toward being primarily constrained by price rather than by satiation (Bickel et al., 2000; Johnson and Bickel, 2006; Hursh and Silberberg, 2008) . Importantly, the essential value (EV) of a reinforcer is related inversely to sensitivity to price (α) and can be calculated from the demand model as follows:
where EV is conceptualized as the strength of a reinforcer to maintain behavior independent of scalar manipulations of reinforcer magnitude and accounting for individual sensitivity to response cost (Hursh and Silberberg, 2008; Hursh, 2014) . Previous work has shown that reinforcer demand models effectively characterize changes in the reinforcement value of non-nicotine rewards, such as food pellets (Cassidy and Dallery, 2012) , food-associated conditioned rewards (Cassidy and Dallery, 2014) , and primary reinforcing sensory stimulation (Barrett and Bevins, 2012; Barrett et al., 2017) .
Progressive ratio and antagonist testing
This phase began 24 h after the last demand-assessment session. Within a single session, lever-pressing was reestablished by the same sucrose-maintained autoshaping procedure described previously. Over the next 15 sessions, responding for VS stabilized on a progressive ratio (PR) schedule of reinforcement. The PR sequence followed an exponential base 2 sequence in one-third logarithmic steps, rounded to the nearest whole number (i.e. 2, 3, 4, 5, 6, 8, 10, 13, 16, etc.) . This sequence was chosen because it included the ratios experienced in the demand-assessment phase and progressed slowly enough to minimize ratio strain in the beginning of ratio progression. This progression also provided the possibility of encountering schedules as high as, or higher than, each
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The purpose of the PR schedule in this phase was to provide a platform, on which to test the effects of α4β2* or α7 receptor antagonism on the reward-enhancing effects of nicotine and varenicline, that reflected the conditions of the demand-assessment phase, but allowed for a rapid assessment over a relatively short period of time. There are advantages and limitations in using a PR schedule compared with a full demand assessment. Namely, the PR schedule allows for a rapid assessment of drug effects on responding constrained by cost within sessions, whereas assessment of the same drug effects in the demand approach requires multiple administrations of the drug across multiple sessions at different FR schedules. Both approaches allow for the assessment of drug effects on behavior in the face of escalating response costs; the PR schedule does so within sessions and the demand approach does so across many sessions. The primary limitation of the PR approach is that there can be no assessment of the cost-consumption relationship because consumption at each cost is not free to vary.
Because we desired to test the effects of receptor antagonism in the same rats from the preceding demand phase, and in the interest of validating the effects of the demand assessment with a second methodological approach, we opted to use the PR schedule in this phase.
Over 36 sessions, rats continued to respond on the PR schedule described above. On these sessions, rats received an injection of either DHβE or MLA, followed by the administration of saline, nicotine (0.4 mg/kg), or varenicline (1.0 mg/kg). Only the higher dose of varenicline from the demand-assessment phase was included in this phase to ensure a high baseline for observing potential decreases in responding brought about by dopamine receptor antagonism. Each antagonist was assessed at three different doses (including a vehicle benchmark), and in combination with saline, nicotine, or varenicline across two determinations, requiring 18 days of testing for each antagonist. Testing with DHβE was completed before testing began with MLA. Sessions were a strict 60 min; the assessment of PR breakpoints was not a goal of this phase. nicotine, DHβE, and MLA) or NIDA (Bethesda, Maryland, USA; varenicline) and dissolved in 0.9% saline. All injections were administered at 1 ml/kg. As per field standards, nicotine dose is reported as base form; all other drug doses are reported as salt form. The pH for nicotine was adjusted to 7.0 0.2 with a NaOH solution. All doses and IPIs were based on published research, including previous work from our laboratory (Liu et al., 2007; Wooters et al., 2009; Levin et al., 2012; Pittenger et al., 2017) . Nicotine was injected subcutaneously; all other drugs were injected intraperitoneally.
Dependent measures and analyses
Total active and inactive lever presses, infrared beam breaks (activity), and VS presentations earned within each session were recorded throughout the experiment. Total VS presentations earned over sessions of the demandassessment phase were analyzed using the exponential reinforcer demand model proposed by Hursh and Silberberg (2008) and the values of Q 0 (consumption at price zero) and α (sensitivity to cost) were calculated from the model fits to the consumption data of individual rats using nonlinear least squares regression. To ensure comparability of α estimates, the range parameter, k, was shared across all eight conditions of sex × drug (k = 1.968). This value was determined by first fitting the demand equation to the data from all conditions across all subjects with the goal of finding a shared estimate for k, and then using that estimate as a constant when fitting the model to the data of individual rats. Estimates of EV were calculated from α and k using Eq. (2). The effects of nicotine and varenicline on Q 0 or EV were analyzed by mixed-factorial analysis of variance with sex as a between-subjects factor and drug as a within-subjects factor. Post-hoc pairwise comparisons were performed upon detection of significant main effects of drug or sex × drug interactions.
The primary measures of interest during the antagonist testing phase were total active lever presses and beam breaks in experimental sessions. These measures were subjected to three-factor, mixed-measures analysis of variance with sex as a between-subjects factor and with drug and antagonist dose conditions as within-subject factors. Each antagonist testing phase (DHβE and MLA) was analyzed separately. Post-hoc pairwise comparisons were performed upon detection of significant interactions. All pairwise comparisons throughout all phases of the study corrected family-wise error rates using the Holm-Bonferroni method with significance set at adjusted P values less than 0.05 (Holm, 1979) .
Results
Assessment of demand for visual stimulus
The demand functions for VS reinforcement between saline, nicotine, and both varenicline dose conditions for males and females are shown in Fig. 1a and b, respectively. The fits of the demand model presented in Fig. 1 are representative curves fit to the data averaged across rats within each condition. All statistical analyses used fits of the demand model to data of individuals. Males and females differed in how quickly they completed the demand-assessment phase by reaching the termination criteria. The point at which 50% of the males or females had reached the termination criteria was FR 64 and FR 128, respectively. One male and one female rat were excluded from demand analyses because the modelgenerated estimates of Q 0 from their data under the saline condition were beyond 1.5 times the interquartile range (i.e. Tukey's hinges; Hoaglin et al., 1983) .
Analysis of Q 0 (Fig. 1c ) discovered a significant main effect of drug [F(3,60) = 18.44, P < 0.001], but not of sex, and no significant interaction (Fs < 1). Further analysis of the main effect of drug found higher Q 0 estimates in the nicotine condition than any other condition (Ps ≤ 0.033). Q 0 was also higher in the 1.0 mg/kg varenicline condition compared with saline (P < 0.001). No significant differences were detected between saline and the 0.1 mg/kg varenicline condition (P = 0.317). Similarly, no significant differences were detected between 0.1 and 1.0 mg/kg varenicline (P = 0.079).
Analysis of EV (Fig. 1d) showed a significant main effect of drug [F(3,60) = 108.3; P < 0.001], but not of sex, and no significant interaction (Fs < 1). Further analysis on the main effect of drug discovered greater EV in the nicotine condition compared with all other conditions (Ps < 0.001). Both varenicline doses enhanced EV relative to saline (Ps < 0.001), and EV was greater in the 1.0 mg/kg condition relative to 0.1 mg/kg varenicline (P = 0.001).
Dihydro-β-erythoidine testing on progressive ratio
Active lever-pressing and locomotor activities on the PR schedule of VS reinforcement across sessions of the DHβE testing phase are shown in Fig. 2a and b. Nicotine and varenicline increased active lever-pressing (Fig. 2a) The presented demand curves are representative fits to averaged data, and not the curves used to generate metrics for statistical analysis. Because individual rats exited the demand-assessment phase upon reaching termination criteria at different FR schedules, data indicating performance at the higher FR schedules are only representative of the subset of the rats who continued through the demand-assessment phase. Specifically, the n for FR 64 was 11 females and nine males, the n for FR 128 was six females and four males, and the n for FR 256 was five females. These data are for presentation purposes only; all analyses were carried out on separate fits of the reinforcer demand model to data from each individual. Post-hoc analysis on the three-factor interaction showed significantly higher active lever-pressing in females than males in the nicotine and varenicline conditions, irrespective of the DHβE dose (Ps ≤ 0.035). No sex differences were observed under saline conditions, irrespective of the DHβE dose (Ps ≥ 0.219). Furthermore, nicotine and varenicline increased active lever-pressing relative to saline in both sexes, across all DHβE dose conditions (Ps ≤ 0.028), except in males at 3.0 mg/kg DHβE (P = 0.084). Active lever-pressing differed between the nicotine and varenicline conditions in males, in the absence of DHβE (P = 0.039), and in females when administered 3.0 mg/kg DHβE (P = 0.004). No differences were observed between nicotine and varenicline conditions under any other conditions of sex or antagonist dose (Ps ≥ 0.554). In females, 3.0 mg/kg DHβE suppressed active lever-pressing relative to saline in all conditions of drug (Ps ≤ 0.039), as did 1.0 mg/kg DHβE in the varenicline condition (P = 0.004), but not the saline or nicotine conditions (P ≥ 0.102). Active lever-pressing was lower following 3.0 mg/kg relative to 1.0 mg/kg DHβE in the nicotine condition for females (P < 0.001).
In males, no effects of DHβE were detected at either dose in either the saline or the varenicline conditions (Ps ≥ 0.941). In the nicotine condition, 3.0 mg/kg DHβE decreased active lever-pressing relative to saline (P = 0.008), but the lower dose did not (P = 0.093); no differences were detected between DHβE doses in the nicotine condition in males (P = 0.615).
Analysis of locomotor activity during the DHβE testing phase (Fig. 2b) ; NS] interaction was significant. The sex × drug × dose interaction was also not significant (F < 1). Further analysis on the sex × drug interaction showed significantly higher locomotor activity in females than in males in the varenicline and nicotine conditions (Ps < 0.001), but not in the saline condition (P = 0.217). In addition, nicotine and varenicline increased locomotor activity relative to saline in females (Ps < 0.001), with no differences detected between nicotine or varenicline conditions (P = 0.551). Varenicline decreased locomotor activity in males relative to saline (P = 0.008), whereas locomotor activity was statistically similar between the nicotine and saline (P = 0.064), and nicotine and varenicline conditions (P = 0.668). 
Methyllycaconitine testing on the progressive ratio
Active lever-pressing and locomotor activity on the PR schedule of VS reinforcement across sessions of the MLA testing phase is shown in the lower panels of Fig. 2 . Analysis of active lever-pressing (Fig. 2a) showed significant main effects of sex [F(1,21) = 7.83; P < 0.02] and drug [F(2,42) = 53.29; P < 0.001], but not of dose [F(2,42) = 1.06; NS]. None of the sex × drug [F(2,42) = 2.84; P = 0.07], sex × dose [F(2,42) = 1.09; NS], and drug × dose (F < 1) interactions were significant. Neither was the sex × drug × dose interaction significant (F < 1). Post-hoc examination of the significant main effects found that active lever-pressing was higher in females than males (P = 0.011), and that nicotine and varenicline increased active lever-pressing relative to saline (Ps < 0.001), with higher active lever-pressing in the nicotine condition relative to varenicline (P = 0.048).
Analysis of locomotor activity during the MLA testing phase (Fig. 2d ) showed significant effects of sex [F(1,21) = 28.21; P < 0.001] and drug [F(2,42) = 6.73; P < 0.005], but not of dose (F < 1). The sex × drug interaction was significant [F(2,42) = 17.52; P < 0.001], but none of the sex × dose [F(2,42) = 1.51; NS], drug × dose interaction (F < 1), or sex × drug × dose [F(4,84) = 1.19; NS] interactions were significant. Further analysis on the sex × drug interaction showed significantly higher locomotor activity in females than in males in the varenicline and nicotine conditions (Ps < 0.001), but not in the saline condition (P = 0.057). In addition, nicotine and varenicline increased locomotor activity relative to saline in females (Ps < 0.001); no significant differences were detected between nicotine or varenicline conditions (P = 0.536). No significant effects of varenicline or nicotine were detected on locomotor activity in males (Ps ≥ 0.214).
Discussion
Nicotine and varenicline increased consumption of VS in males and females across a broad range of response costs. The reinforcer demand analysis found that in both sexes, nicotine and varenicline increased the intensity of demand (Q 0 ) and EV of VS reinforcement. Note that Q 0 and EV represent different facets of the reinforcement value construct; Q 0 reflects value as consumption where the only constraint on behavior is satiation, whereas EV represents value as sensitivity to cost independent of scalar changes in reinforcer quantity and yet reflective of reinforcer quality (cf. Hursh and Silberberg, 2008; Barrett and Bevins, 2012; Barrett et al., 2017) . Therefore, the finding that nicotine and varenicline enhanced the value represented by both Q 0 and EV is noteworthy because it suggests that both drugs enhanced VS reinforcement value by decreasing both the impact of satiation and sensitivity to cost in males and females. This finding replicates what we reported in Barrett et al. (2017) on nicotine, while extending those findings with a side-byside comparison with varenicline in the present report.
Furthermore, nicotine and varenicline increased active lever-pressing maintained by a PR schedule of VS reinforcement during both antagonist testing phases. Notably, both drugs also produced locomotor activation in females, but not in males. Administration of 3.0 mg/kg DHβE attenuated enhancement of active lever-pressing by nicotine in both sexes, without affecting locomotor activation by either drug. Interestingly, DHβE also decreased active lever-pressing in both the saline and the varenicline conditions in females, but only in the nicotine condition in males. Treatment with MLA produced no significant effects on active lever-pressing or locomotor activity in either sex across all drug conditions. Together with the reinforcer demand analyses, these findings suggest that both nicotine and varenicline enhance the value of sensory reinforcement in males and females, but suggest potential differences in enhancement between nicotine and varenicline and the expression of these effects between the sexes.
In terms of the enhancing effects of varenicline relative to those of nicotine, although both drugs showed largely parallel enhancing effects on Q 0 and EV of VS reinforcement, the enhancement effects of nicotine were consistently greater than those of varenicline. In addition, neither the effects of nicotine nor varenicline on the demand metrics of value differed by sex. In contrast, in Barrett et al. (2017) , we found that the enhancing effects of bupropion on Q 0 and EV of VS reinforcement reached equivalent levels to those of nicotine, but showed marked differences in sex, with greater enhancement by bupropion in females than in males. Combined, these studies provide a clear demonstration that nicotine reliably enhances the value of sensory reinforcers irrespective of sex. In addition, both studies show that commonly prescribed smoking-cessation aids, namely bupropion (Zyban) and varenicline (Chantix), produce valueenhancing effects such as those of nicotine, which may account in part for their clinical efficacy. Finally, these findings suggest that important differences likely exist in the biological mechanisms of the value-enhancing effects of nicotine, varenicline, and bupropion (pharmacologically, behaviorally, or both).
Varenicline has a complex pharmacological profile on nAChRs, but its clinical efficacy as a smoking-cessation aid is believed to result from its partial agonist/antagonist activity at α4β2* receptors, both mimicking and antagonizing the effects of nicotine at these receptors (Mihalak et al., 2006) . Varenicline acts as a full agonist at α7 receptors with high binding affinity, and activates α6β2* and α3β4* receptors (Mihalak et al., 2006; Rollema et al., 2007; Grady et al., 2010; Bordia et al., 2012; Ortiz et al., 2012) . Antagonism by DhβE, but not MLA, in the present study suggests that activation of α4β2* receptors, but not α7 receptors, plays a critical role in the Value enhancement by nicotinic agonists Barrett et al. 499 value-enhancing effects of varenicline. Notably, this is a feature that it shares with nicotine, in which activation of α4β2-containing receptors has been implicated in both the primary reinforcing and the value-enhancing effects of nicotine . However, recent findings suggest that varenicline does not appear to have primary reinforcing effects, despite sharing a mechanism of action with nicotine at α4β2* receptors (Schassburger et al., 2015) . In addition, DHβE also works as an antagonist at receptors containing the α6β2 and α3β4 subunits (Harvey and Leutje, 1996; ; the potential role of these other subunits in the valueenhancing effects of varenicline or nicotine has not been investigated. Together, these findings suggest that the α4β2* nAChRs may not be solely responsible for the value-enhancing effects of nicotine and varenicline, but that some other receptor subtype also antagonized by DHβE may also be involved, such as α6β2* or α3β4* nAChRs (Schassburger et al., 2015) . Further investigation using more specific receptor antagonists, such as AT-1001 (Toll et al., 2012) , or knockout gene expression may be critical in further elucidating the mechanisms by which nicotine and varenicline enhance reinforcement value.
The present report adds to previous findings that the value-enhancing effects of nicotine are distinct from its locomotor-activating effects (Barrett and Bevins, 2013; Barrett et al., 2017) , and extends these findings to varenicline. Note that although nicotine and varenicline produced robust enhancing effects on active lever-pressing in both sexes throughout the experiment, locomotor activation by nicotine or varenicline was only evident in females. Indeed, nicotine produced no detectable locomotor activation in males, and varenicline even produced locomotor decreases in males while simultaneously increasing active lever-pressing (cf. DHβE testing phase). Together with previous findings that have shown similar dissociations between the value-enhancing effects and locomotoractivating effects of nicotine Bevins, 2012, 2013; Barrett et al., 2017) , the present findings suggest that locomotor activation is not a necessary component of value enhancement by nicotine. That is not to say, however, that the locomotor-stimulating effects of drugs cannot interact with or modify the expression of its separate valueenhancing effects. It is possible that the combination of locomotor activation and value enhancement may lead to enhancement of operant behavior above and beyond circumstances where value enhancement occurs in the absence of locomotor effects. That is, expression of druginduced value enhancement may be more pronounced in animals whose locomotor behavior has been markedly activated. Future research may consider investigating the interaction between locomotor activation and value enhancement by drugs that produce either or both effects (cf. Swalve et al., 2015) .
In the present study, no sex differences were observed in the demand metrics of the reinforcement value produced by nicotine or varenicline, or under saline conditions. However, sex differences in rates of active lever-pressing under the PR schedule were reliably evident across the nicotine and varenicline conditions, and to a lesser extent in the saline condition. The discrepancy in sex differences between the demand metrics and active leverpressing on the PR schedule likely stems from sex differences in responding that are only evident at sufficiently high constraints of response cost. Indeed, similar trends in active lever-pressing are evident in the nicotine and 1.0 mg/kg varenicline conditions during the demandassessment phase (data not shown). However, because rats exited the demand-assessment phase at different FR schedules, on the basis of when they fulfilled the termination criterion, an unbiased analysis of betweensubject effects on active lever-pressing at high response costs is impossible in the present study. To this end, the PR schedule used here was designed to mimic the FR progression of the demand assessment while providing enough pressure on responding to detect effects on responding when responding was constrained primarily by cost. The present findings suggest that female rats may be more sensitive than males to the sensory reinforcement of VS and the enhancement of VS reinforcement by nicotine and varenicline under sufficiently high constraints of response cost.
In the present study, lever-pressing was maintained by a VS that functioned as sensory reinforcement in individually housed, Sprague-Dawley rats. There are a variety of benefits to using sensory reinforcement in the present preparation, but also a variety of theoretical quandaries. Namely, issues of consumption and satiation are somewhat convoluted when applied to sensory reinforcers, whose features and functions deviate from more commonly studied primary reinforcers such as food, water, or drugs. Consider the previous statement that the demand metric Q 0 reflects consumption when the only constraint on behavior is satiation; this interpretation is intuitive and straightforward with a classic reinforcer such as food, but what exactly is satiety to a VS? Notably, the subjects in the present study were individually housed albino rats who spent most of their time in relatively Spartan environmental conditions. This particular arrangement may represent a form of sensory deprivation that gives the VS its capacity to function as a mild reinforcer. Although such theoretical discussions are beyond the scope of this report, for the present, we assume that sensory reinforcers follow the same general principles as more traditional reinforcers.
The present study replicates the findings of Barrett et al. (2017) for nicotine, which also found no differences in Q 0 or EV between the sexes in the saline or nicotine conditions. By contrast, Barrett et al. (2017) reported higher Q 0 in females than males when administered 10 mg/kg bupropion, and greater EV in females than males in the 10 and 20 mg/kg bupropion conditions. Together, these findings suggest that value enhancement by nicotine is similar between the sexes and extends that finding to varenicline. Moreover, the present findings show the critical involvement of α4β2* nAChRs in the value-enhancing effects of nicotine and varenicline. Conversely, the valueenhancing effects of bupropion are sex sensitive and are mediated by dopaminergic and noradrenergic, and not cholinergic mechanisms Barrett et al., 2017) . Importantly, bupropion and varenicline are effective, Food and Drug Administration-approved pharmacotherapies for smoking cessation. Future research should investigate the role that value-enhancement replacement by bupropion and varenicline may play in the efficacy of both agents as smoking-cessation aids. If value enhancement by these agents is critical to their efficacy as pharmacotherapies, then perhaps bupropion and varenicline may be differentially effective treatments for men and women attempting to quit smoking. Alternatively, differences in sensitivity to the value-enhancing effects of bupropion and varenicline may also be accompanied by differences in sensitivity to the side effects of both these agents for tobacco-abstaining patients. Nonetheless, an extension of the present findings to human populations of smokers with special attention to the biobehavioral mechanisms of value-enhancement promises to be a fruitful endeavor and may provide insights into the best practices toward treating tobacco dependence between the sexes.
